Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection and Other Conditions in Children

A Joint Position Paper From the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition

and the FMT Special Interest Group of the North American Society of Pediatric Gastroenterology Hepatology, Nutrition, the European Society for Pediatric Gastroenterology Hepatology, Nutrition

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Fecal microbiota transplantation (FMT) is becoming part of the treatment algorithms against recurrent Clostridium difficile infection (rCDI) both in adult and pediatric gastroenterology practice. With our increasing recognition of the critical role the microbiome plays in human health and disease, FMT is also being considered as a potential therapy for other disorders, including inflammatory bowel disease (Crohn disease, ulcerative colitis), graft versus host disease, neuropsychiatric diseases, and metabolic syndrome. Controlled trials with FMT for rCDI have not been performed in children, and numerous clinical and regulatory considerations have to be considered when using this untraditional therapy. This report is intended to provide guidance for FMT in the treatment of rCDI in pediatric patients.

Original languageEnglish (US)
Pages (from-to)130-143
Number of pages14
JournalJournal of pediatric gastroenterology and nutrition
Volume68
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Clostridium Infections
Clostridium difficile
Gastroenterology
Joints
Pediatrics
Microbiota
Metabolic Diseases
Graft vs Host Disease
Therapeutics
Ulcerative Colitis
Inflammatory Bowel Diseases
Crohn Disease
Fecal Microbiota Transplantation
Health

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Gastroenterology

Cite this

@article{cb885a33e5e54c87974373fb5eab966d,
title = "Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection and Other Conditions in Children: A Joint Position Paper From the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition",
abstract = "Fecal microbiota transplantation (FMT) is becoming part of the treatment algorithms against recurrent Clostridium difficile infection (rCDI) both in adult and pediatric gastroenterology practice. With our increasing recognition of the critical role the microbiome plays in human health and disease, FMT is also being considered as a potential therapy for other disorders, including inflammatory bowel disease (Crohn disease, ulcerative colitis), graft versus host disease, neuropsychiatric diseases, and metabolic syndrome. Controlled trials with FMT for rCDI have not been performed in children, and numerous clinical and regulatory considerations have to be considered when using this untraditional therapy. This report is intended to provide guidance for FMT in the treatment of rCDI in pediatric patients.",
author = "{and the FMT Special Interest Group of the North American Society of Pediatric Gastroenterology Hepatology, Nutrition, the European Society for Pediatric Gastroenterology Hepatology, Nutrition} and Davidovics, {Zev H.} and Sonia Michail and Nicholson, {Maribeth R.} and Kociolek, {Larry Kenneth} and Nikhil Pai and Richard Hansen and Tobias Schwerd and Aldo Maspons and Raanan Shamir and Hania Szajewska and Nikhil Thapar and {de Meij}, Tim and Alexis Mosca and Yvan Vandenplas and Kahn, {Stacy A.} and Richard Kellermayer",
year = "2019",
month = "1",
day = "1",
doi = "10.1097/MPG.0000000000002205",
language = "English (US)",
volume = "68",
pages = "130--143",
journal = "Journal of Pediatric Gastroenterology and Nutrition",
issn = "0277-2116",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection and Other Conditions in Children : A Joint Position Paper From the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. / and the FMT Special Interest Group of the North American Society of Pediatric Gastroenterology Hepatology, Nutrition, the European Society for Pediatric Gastroenterology Hepatology, Nutrition.

In: Journal of pediatric gastroenterology and nutrition, Vol. 68, No. 1, 01.01.2019, p. 130-143.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection and Other Conditions in Children

T2 - A Joint Position Paper From the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition

AU - and the FMT Special Interest Group of the North American Society of Pediatric Gastroenterology Hepatology, Nutrition, the European Society for Pediatric Gastroenterology Hepatology, Nutrition

AU - Davidovics, Zev H.

AU - Michail, Sonia

AU - Nicholson, Maribeth R.

AU - Kociolek, Larry Kenneth

AU - Pai, Nikhil

AU - Hansen, Richard

AU - Schwerd, Tobias

AU - Maspons, Aldo

AU - Shamir, Raanan

AU - Szajewska, Hania

AU - Thapar, Nikhil

AU - de Meij, Tim

AU - Mosca, Alexis

AU - Vandenplas, Yvan

AU - Kahn, Stacy A.

AU - Kellermayer, Richard

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Fecal microbiota transplantation (FMT) is becoming part of the treatment algorithms against recurrent Clostridium difficile infection (rCDI) both in adult and pediatric gastroenterology practice. With our increasing recognition of the critical role the microbiome plays in human health and disease, FMT is also being considered as a potential therapy for other disorders, including inflammatory bowel disease (Crohn disease, ulcerative colitis), graft versus host disease, neuropsychiatric diseases, and metabolic syndrome. Controlled trials with FMT for rCDI have not been performed in children, and numerous clinical and regulatory considerations have to be considered when using this untraditional therapy. This report is intended to provide guidance for FMT in the treatment of rCDI in pediatric patients.

AB - Fecal microbiota transplantation (FMT) is becoming part of the treatment algorithms against recurrent Clostridium difficile infection (rCDI) both in adult and pediatric gastroenterology practice. With our increasing recognition of the critical role the microbiome plays in human health and disease, FMT is also being considered as a potential therapy for other disorders, including inflammatory bowel disease (Crohn disease, ulcerative colitis), graft versus host disease, neuropsychiatric diseases, and metabolic syndrome. Controlled trials with FMT for rCDI have not been performed in children, and numerous clinical and regulatory considerations have to be considered when using this untraditional therapy. This report is intended to provide guidance for FMT in the treatment of rCDI in pediatric patients.

UR - http://www.scopus.com/inward/record.url?scp=85059225507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059225507&partnerID=8YFLogxK

U2 - 10.1097/MPG.0000000000002205

DO - 10.1097/MPG.0000000000002205

M3 - Article

VL - 68

SP - 130

EP - 143

JO - Journal of Pediatric Gastroenterology and Nutrition

JF - Journal of Pediatric Gastroenterology and Nutrition

SN - 0277-2116

IS - 1

ER -